-
Zai Lab Ltd Reports 31% YOY Growth in Product Revenues and Strategic Pipeline Expansion
•
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has released its financial results for 2023, along with updates on product highlights and corporate developments. The company reported total product revenues of USD 266.7 million for the year, marking a 31% year-on-year growth at constant exchange rates. This…
-
Harbour BioMed Partners with Boostimmune to Develop Novel ADC Therapies
•
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the US, and the Netherlands, has announced an antibody drug conjugate (ADC) discovery cooperation agreement with South Korea-based ADC specialist Boostimmune, Inc. The financial details of the agreement have not been disclosed. As per the terms…
-
China’s NMPA Updates Rules for Administrative Penalty Discretions in Drug Supervision
•
The National Medical Products Administration (NMPA) has issued the “Rules for the Application of Administrative Penalty Discretions in Drug Supervision and Administration,” which will come into effect on August 1, 2024. These Rules, comprising 6 chapters and 54 articles, represent an enhancement of the 2012 version, with improvements in four…
-
AstraZeneca’s Fasenra Matches Nucala in EGPA Trial and Shows Steroid Reduction Benefits
•
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has presented results from a Phase III trial that previously announced the non-inferiority of its IL-5 antagonist Fasenra (benralizumab) against GlaxoSmithKline’s (GSK; NYSE: GSK) Nucala (mepolizumab), the current standard of care for relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). The data revealed…
-
BeiGene’s Tislelizumab Receives CHMP Recommendation for Three NSCLC Indications in Europe
•
BeiGene (NASDAQ: BGNE) has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended its programmed death-1 (PD-1) inhibitor tislelizumab for a marketing license for three non-small cell lung cancer (NSCLC) indications. The CHMP’s positive opinion is for: Patients with EGFR or ALK mutation-positive…
-
Shanghai Fosun Pharmaceutical Partners with Nanning City to Broaden Collaboration in Biopharma and Beyond
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196，HKG: 2196), a Chinese pharmaceutical heavyweight, has entered into a strategic partnership with Nanning City in Guangxi province, China’s gateway to the ASEAN region. The collaboration aims to explore opportunities in biopharmaceuticals, intelligent manufacturing, finance and insurance, commerce, culture, tourism, and other sectors.…
-
Everest Medicines Gets CDE Approval for Global Phase IIb Study of Zetomipzomib in Lupus Nephritis
•
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval from the Center for Drug Evaluation (CDE) to proceed with the global, placebo-controlled Phase IIb PALIZADE study. The study aims to assess the efficacy and safety of zetomipzomib in patients with active lupus nephritis (LN).…
-
Alvotech Scores FDA Nod for Interchangeable High-Concentration Biosimilar to Humira
•
The US Food and Drug Administration (FDA) has granted approval to Iceland-based Alvotech’s (NASDAQ: ALVO) Simlandi, marking it as the first interchangeable high-concentration, citrate-free biosimilar to AbbVie’s (NYSE: ABBV) immunosuppressant Humira (adalimumab). Humira faced patent expiration in the US last year, leading to biosimilar competition. Simlandi is approved for various…
